BridgeBio Pharma (BBIO) Stock Analysis
This is a peer-relative look at BridgeBio Pharma (BBIO): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | BBIO |
|---|---|
| Name | BridgeBio Pharma Inc. |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology |
| GICS Sub-Industry | Biotechnology |
| Market Capitalization | 14.47 billion USD |
| Currency | USD |
| Exchange | Nasdaq |
| Listing Date | June 27, 2019 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| Total Return (1Y) | 22.70% | 24.62% |
| Total Return (3Y, Annualized) | 40.97% | 20.37% |
| Total Return (5Y, Annualized) | 8.25% | -4.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 44.39% | 66.36% |
| Beta (5Y) | 0.93 | 0.93 |
| Max Drawdown (5Y) | -89.79% | -80.19% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 0.41 | 0.36 |
| Sortino Ratio (1Y) | 0.63 | 0.58 |
Profitability
ROE (TTM)
No usable ROE is available for BridgeBio Pharma (BBIO) this period, so the shareholder-equity return read is skipped.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- BBIO
- --
Largest peers
- LLY
- 86.02%
- NVS
- 24.33%
- AZN
- 22.57%
- JNJ
- 20.02%
- MRK
- 5.06%
- BBIO
- --
- ABBV
- --
Net Margin (TTM)
BridgeBio Pharma (BBIO) has negative net margin of -59.84%. The trailing period ended in a net loss, so the bottom-line conversion read is a warning rather than a profitability strength.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-59.84%
Group distribution
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BBIO
- -59.84%
Largest peers
- LLY
- 31.90%
- AZN
- 17.68%
- NVS
- 17.49%
- JNJ
- 16.20%
- ABBV
- 15.67%
- MRK
- 3.64%
- BBIO
- -59.84%
Operating Margin (TTM)
BridgeBio Pharma (BBIO) has negative operating margin of -3.30%. Core operations were loss-making before interest and taxes over the trailing period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-3.30%
Group distribution
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- BBIO
- -3.30%
- Q1
- -78.82%
- Min
- -207.40%
Largest peers
- LLY
- 53.66%
- ABBV
- 39.59%
- MRK
- 35.22%
- NVS
- 34.27%
- AZN
- 29.57%
- JNJ
- 25.74%
- BBIO
- -3.30%
Profitability Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| ROE (TTM) | -- | -26.66% |
| ROA (TTM) | -13.97% | -12.50% |
| Net Margin (TTM) | -59.84% | 0.00% |
| Operating Margin (TTM) | -3.30% | 0.00% |
| Gross Margin (TTM) | 94.34% | 37.87% |
Growth
Revenue Growth
BridgeBio Pharma (BBIO) grew revenue 126.26%, in the upper peer quartile. The top line is expanding faster than at most industry peers, which points to share gains or stronger pricing.
EPS Growth
No usable EPS growth is available for BridgeBio Pharma (BBIO) this period, so the earnings-momentum read is skipped.
Growth Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | 126.26% | 11.45% |
| Revenue Growth (3Y CAGR) | 86.30% | 9.94% |
| EPS Growth (YoY) | -- | 4.28% |
| EPS Growth (3Y CAGR) | -- | 4.17% |
Financial Strength
Current Ratio (MRQ)
BridgeBio Pharma (BBIO) has current ratio of 2.09, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
Group distribution
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BBIO
- 2.09
- Min
- 0.10
Largest peers
- BBIO
- 2.09
- LLY
- 1.39
- MRK
- 1.35
- JNJ
- 1.02
- AZN
- 1.01
- NVS
- 0.88
- ABBV
- 0.87
Debt / Equity (MRQ)
No usable debt-to-equity ratio is available for BridgeBio Pharma (BBIO) this period, so the balance-sheet leverage read is skipped.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- BBIO
- --
Largest peers
- NVS
- 1.29
- LLY
- 1.23
- MRK
- 1.20
- AZN
- 0.66
- JNJ
- 0.55
- BBIO
- --
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 2.09 | 5.52 |
| Debt / Equity (MRQ) | -- | 0.15 |
| Net Debt / EBITDA | -- | 1.08 |
Dividends
Dividend Yield (TTM)
BridgeBio Pharma (BBIO) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.88%
- ABBV
- 2.40%
- MRK
- 2.29%
- JNJ
- 1.94%
- AZN
- 1.73%
- LLY
- 0.49%
- BBIO
- 0.00%
Dividend Payout Ratio (TTM)
BridgeBio Pharma (BBIO) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 343.43%
- ABBV
- 117.35%
- NVS
- 90.46%
- JNJ
- 80.12%
- AZN
- 45.38%
- LLY
- 21.71%
- BBIO
- 0.00%
Dividend Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
No usable P/E ratio is available for BridgeBio Pharma (BBIO) this period, so the trailing-earnings valuation read is skipped.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BBIO
- --
Largest peers
- MRK
- 148.21
- ABBV
- 50.05
- LLY
- 43.95
- JNJ
- 41.92
- NVS
- 31.02
- AZN
- 26.37
- BBIO
- --
P/S Ratio (TTM)
BridgeBio Pharma (BBIO) trades at 15.31 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.31
Group distribution
- Max
- 58.18
- Q3
- 25.77
- BBIO
- 15.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
Largest peers
- BBIO
- 15.31
- LLY
- 13.95
- ABBV
- 7.80
- JNJ
- 6.69
- MRK
- 5.37
- NVS
- 5.35
- AZN
- 4.63
P/B Ratio (MRQ)
BridgeBio Pharma (BBIO) has negative P/B ratio of -5.59, which means reported book equity is negative. Price-to-book breaks down in this situation and should not be used as a valuation signal.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.59
Group distribution
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BBIO
- -5.59
- Min
- -5.59
Largest peers
- LLY
- 29.96
- NVS
- 8.25
- JNJ
- 8.16
- MRK
- 8.06
- AZN
- 5.59
- BBIO
- -5.59
- ABBV
- -112.34
Valuation Metrics
| Metric | Current stock: BBIO | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | -- | 26.69 |
| P/S Ratio (TTM) | 15.31 | 7.30 |
| P/B Ratio (MRQ) | -5.59 | 3.25 |
| Free Cash Flow Yield (TTM) | -1.98% | -1.66% |